Abstract:Background: Regulatory applications for cell therapy face more objections compared to conventional small molecule or biological drugs, leading to delays in market approval and clinical adoption. Increased regulatory objections frequently relate to issues regarding preclinical evidence, such as experimental design of animal studies, selection of animal models, endpoints, and determination of mechanism of action. Synthesis and clarification of the preclinical evidence necessary to demonstrate treatment efficacy and advance into early-phase clinical trials is needed to help researchers avoid regulatory objections. Methods: We conducted a scoping review in which we searched repositories of the International Council for Harmonisation and all national member organizations (N = 38) for documents related to preclinical studies of cell therapies. Active guidance documents related to cell therapy were included, with no restrictions based on the year or language of publication. Data extraction was conducted in duplicate with conflicts resolved through consensus discussion. Results: From 1215 identified documents, a total of 182 were included and analyzed, with 71% originating from ten major regulatory agencies. The most prevalent preclinical item addressed was the mechanism of action (n = 161, 88% of documents), underscoring its importance in bridging preclinical findings to clinical application. Most documents (n = 140, 77%) emphasized the importance of using clinically relevant preclinical models, though specific recommendations on models of disease were less common (n = 81, 45%). Selection of clinically relevant intervention parameters (n = 136, 75%) and outcome measures (n = 121, 66%) were also frequently recommended, but selection of relevant comparator groups appeared less frequently (n = 35, 19%). Furthermore, robust study design elements such as randomization and blinding were less frequently recommended, appearing in 31% of documents (n = 57). Comparison with clinical trial guidance revealed a significant gap in the rigor of study design recommendations for preclinical research. Conclusions: Regulatory guidance for preclinical efficacy studies often recommends a strong emphasis on the clinical relevance of animal models, intervention parameters, outcomes, and mechanism of action. Incorporating these recommendations into early preclinical studies should improve the acceptability of preclinical evidence for approval by the relevant national regulators and can be used as a guide to ensure that all evidence that regulators say they expect is efficiently assembled into new clinical trial applications.

Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development

Best Practices in qPCR and dPCR Validation in Regulated Bioanalytical Laboratories

qPCR and qRT-PCR analysis: Regulatory points to consider when conducting biodistribution and vector shedding studies

Drug Regulatory-Compliant Validation of a qPCR Assay for Bioanalysis Studies of a Cell Therapy Product with a Special Focus on Matrix Interferences in a Wide Range of Organ Tissues

Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies

Applications of Digital Polymerase Chain Reaction (dPCR) in Molecular and Clinical Testing

Digital PCR for the characterization of reference materials

Development of digital PCR molecular tests for clinical practice: principles, practical implementation and recommendations.

Proceedings: International Regulatory Considerations on Development Pathways for Cell Therapies

Synthesizing regulatory guidance for demonstrating preclinical efficacy and translating promising cell therapies to early phase clinical trials: a scoping review

Bioanalytical Methods for Characterization of CAR-T Cellular Kinetics: Comparison of PCR Assays and Matrices

Anti-drug Antibody Validation Testing and Reporting Harmonization

Immunogenicity Risk Assessment of Process-related Impurities in an Engineered T cell Receptor Cellular Product

Using qPCR and ddPCR to study biodistribution of cell therapy products: a multi-site evaluation

The need for robust qPCR‐based eDNA detection assays in environmental monitoring and species inventories

Assessing Tumorigenicity in Stem Cell-Derived Therapeutic Products: A Critical Step in Safeguarding Regenerative Medicine

Regulating molecular diagnostic assays: developing a new regulatory structure for a new technology

An industry perspective approach and control strategy for implementation of ready-to-use cells in bioassays: survey outcome and recommendations

A Comprehensive ddPCR Strategy for Sensitive and Reliable Monitoring of CAR-T Cell Kinetics in Clinical Applications

Data Exploration, Quality Control and Testing in Single-Cell qPCR-Based Gene Expression Experiments

Recommendations for the Development and Validation of Neutralizing Antibody Assays in Support of Biosimilar Assessment